Skip to content

FDA approves Moderna’s mRNA flu vaccine mFLUSIVA for older adults

scienceAug 6, 2026565,238

The Food and Drug Administration approved Moderna’s mRNA seasonal flu vaccine mFLUSIVA for adults 50 and older. Moderna said mFLUSIVA is expected to be available for people 50 and older for the 2026, 2027 respiratory illness season. In a clinical trial of adults 50 to 64, the mRNA vaccine produced 27 percent fewer confirmed flu cases than the current standard vaccine; overall safety profiles were similar but more people receiving the mRNA shot reported mostly mild side effects that lasted two days or less. For people 65 and older, the high-dose vaccine is currently recommended; Moderna said it will collect data this winter comparing mFLUSIVA to the high-dose vaccine and submit those results to the FDA to determine whether approval will extend to that age group. The FDA initially declined to review Moderna’s application earlier this year but reversed course after Moderna promised a postmarket study and following public outcry. Health Secretary Robert F. Kennedy Jr. canceled at least 500 million dollars of federally funded mRNA vaccine development last year and has voiced opposition to the mRNA platform; the articles say he claimed funding should go to other platforms and falsely asserted mRNA vaccines can prolong pandemics. The CDC continues to recommend annual flu vaccination for everyone 6 months and older and recommends getting vaccinated before the end of October.

Dr. Lucky Tran
@luckytran.com

Fantastic news! The FDA has approved the first mRNA flu vaccine. Using mRNA technology will make it easier to update each season’s flu vaccine to keep up with new variants.

243845d ago
3 sources